Celanese reports agreement with Population Council for VitalDose DDP

Celanese Corporation announced that it has entered into an agreement with the Population Council to supply its VitalDose Drug Delivery Platform for use in a new Multipurpose Prevention Technology Intravaginal Ring. The IVR is being developed to provide both contraception and protection against HIV and is currently in a phase 1b clinical trial. “Our data indicate that women overwhelmingly prefer, and are more likely to use, a multipurpose prevention product that prevents pregnancy and sexually transmitted infection acquisition over a product that prevents only one of the two,” said Brid Devlin, Chief Scientific Officer of Product Development at the Population Council. “This IVR would address the need for a contraceptive solution while also providing preventive therapy against HIV at a time when 63 percent of new HIV infections are contracted by women and girls.”